Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394183 | 1.00 | DPP4 (0.68) | DPP4DPP8 | |
| SCHEMBL3389637 | 0.89 | DPP4 (0.69) | DPP4 | |
| SCHEMBL3389639 | 0.89 | DPP4 (0.69) | DPP4 | |
| SCHEMBL3388737 | 0.89 | DPP4 (0.69) | DPP4DPP8 | |
| SCHEMBL3388739 | 0.89 | DPP4 (0.69) | DPP4DPP8 | |
| SCHEMBL6428417 | 0.88 | DPP4 (0.53) | DPP4DPP8 | |
| SCHEMBL15300603 | 0.84 | DPP4 (0.63) | DPP4 | |
| SCHEMBL15300602 | 0.84 | DPP4 (0.63) | DPP4 | |
| SCHEMBL18851336 | 0.83 | DPP4 (0.66) | DPP4 | |
| SCHEMBL204349 | 0.81 | DPP4 (1.00) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790736-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | claimed |
| EP-1911754-A1 | Dipeptidyl peptidase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | claimed |
| EP-1506967-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | claimed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | claimed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1911754-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-7790736-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7723344-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7579357-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-25 | — | — | US | disclosed |
| US-7470700-B2 | Such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-1911754-A1 | Dipeptidyl peptidase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1506967-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070530-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885 |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885 |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885 |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885 |
| US-20050070530-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.